German University Study Endorses Uscom Australia’s Non-Invasive Ultra-Sound Cardiac Output Monitor For Critical Care Patients
06 June 2012 - 12:59AM
Business Wire
Australian non-invasive cardiac monitoring company Uscom Limited
(ASX: UCM) today announced the publication of new independent peer
reviewed research demonstrating the use of its product as a
standard of care for accurate and important cardiac monitoring of
critical care patients on ventilators.
The study performed on patients with pneumonia and septic shock
admitted to the Intensive Care Unit of
Ludwig-Maximilians-University Munich found the USCOM monitor was,
“an accurate, easy to use, non-invasive device that detected
irregularities in heart function and helped guide medical
treatment.”
The results published in Acta Cardiology found, “USCOM
constitutes an important tool for easy, rapid and reliable
diagnosis and haemodynamic monitoring of critically ill
patients.”
The non-invasive cardiac monitoring device has major
applications in paediatrics, emergency and intensive care medicine
and anesthesia, as well as for management of adult and paediatric
sepsis, hypertension, heart failure and for the guidance of
cardiovascular fluid and drug therapy.
The study identified the accurate calibration of ventilators as
an important clinical application for the patent protected USCOM
platform technology, and a new and substantial market.
Uscom Limited Chairman Rob Phillips said, “This study shows
ventilators should be calibrated with USCOM. This is more far
reaching, practice changing research which at some time will shift
the medical monitoring market. Our sector dominating evidence has
great value, and our focus is now to develop partnerships with
established marketing, distribution and sales organisations which
can efficiently and with scale deliver the USCOM technology into
multiple revenue opportunities rapidly as practice responds to our
mounting evidence.“
“These partnerships will allow us to deliver modular versions of
USCOM into portable ultrasound units, monitoring suites, and now
into ventilators, as well as continue with stand-alone sales into
current and new markets. These licensing partnerships are envisaged
to deliver strong profitability to shareholders and be the
foundation of the Uscom of the future.”
Ventilation of patients with impaired lung function is an
increasingly common treatment in critical care medicine and
inappropriate ventilator settings can impair cardiac function,
making the patient worse. So an accurate measurement of cardiac
output is critical for determining the optimal ventilation
settings. Currently cardiac monitoring during ventilation is
infrequent because the monitoring methods are invasive and/or
inaccurate.
USCOM is approved for use by the US Food & Drug
Administration (FDA) and is sold in North America, South America,
Europe, the Middle East, Australia, New Zealand, China and South
East Asia.
For more information contact: Rob Phillips Executive Chairman
Uscom Limited E: rob@uscom.com.au or + 61 2 9247 4144
www.uscom.com.au
References: Horster S, Stemmler HJ, Sparrer J, Tischer T,
Hausman A, Geiger S. Mechanical ventilation with positive
end-expiratory pressure in critically ill patients: comparison of
CW-Doppler ultrasound cardiac output monitoring (USCOM) and
thermodilution (PiCCO). Acta Cardiol 2012; 67(2): 177-185, doi:
10.2143/AC.67.2.2154208
Uscom (ASX:UCM)
Historical Stock Chart
From Dec 2024 to Jan 2025
Uscom (ASX:UCM)
Historical Stock Chart
From Jan 2024 to Jan 2025
